Medical management of Crohn’s disease: state of the art and future perspectives
Over the past decade, the improvement in the understanding of the molecular mechanisms of Crohn’s disease (CD) led to the development of more targeted therapies, including biologics - i.e. monoclonal antibodies that selectively block key mediators of inflammation - and novel small molecule drugs - i...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2019-09-01
|
| Series: | Italian Journal of Medicine |
| Subjects: | |
| Online Access: | https://www.italjmed.org/index.php/ijm/article/view/1194 |
| _version_ | 1797428548062937088 |
|---|---|
| author | Fabio Salvatore Macaluso |
| author_facet | Fabio Salvatore Macaluso |
| author_sort | Fabio Salvatore Macaluso |
| collection | DOAJ |
| description | Over the past decade, the improvement in the understanding of the molecular mechanisms of Crohn’s disease (CD) led to the development of more targeted therapies, including biologics - i.e. monoclonal antibodies that selectively block key mediators of inflammation - and novel small molecule drugs - i.e. compounds with a molecular weight <1 kDa able to diffuse through cell membranes and then fit for the oral route of administration - which will enrich the therapeutic armamentarium of CD soon. In parallel with the expansion of the medical options, the therapeutic targets to be achieved in patients with CD have changed. In particular, we moved from the simple control of symptoms to more ambitious goals which aim to permanently extinguish the inflammation, even the subclinical one. As a consequence, the role of some of the conventional drugs which have been used in CD for several years, such as 5-aminosalicylates and conventional immunosuppressants, is becoming more limited in favor of these new drugs. This profound modification of CD therapy and the intrinsic complexity of the disease are relevant to the point that the management of inflammatory bowel diseases is gradually becoming a subspecialty in the field of gastroenterology or internal medicine. |
| first_indexed | 2024-03-09T09:00:29Z |
| format | Article |
| id | doaj.art-ab819cd33c954908974a18eb14cc045a |
| institution | Directory Open Access Journal |
| issn | 1877-9344 1877-9352 |
| language | English |
| last_indexed | 2024-03-09T09:00:29Z |
| publishDate | 2019-09-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Italian Journal of Medicine |
| spelling | doaj.art-ab819cd33c954908974a18eb14cc045a2023-12-02T11:50:24ZengPAGEPress PublicationsItalian Journal of Medicine1877-93441877-93522019-09-0113310.4081/itjm.2019.1194Medical management of Crohn’s disease: state of the art and future perspectivesFabio Salvatore Macaluso0Department of Medicine, Villa Sofia-Cervello Hospital, PalermoOver the past decade, the improvement in the understanding of the molecular mechanisms of Crohn’s disease (CD) led to the development of more targeted therapies, including biologics - i.e. monoclonal antibodies that selectively block key mediators of inflammation - and novel small molecule drugs - i.e. compounds with a molecular weight <1 kDa able to diffuse through cell membranes and then fit for the oral route of administration - which will enrich the therapeutic armamentarium of CD soon. In parallel with the expansion of the medical options, the therapeutic targets to be achieved in patients with CD have changed. In particular, we moved from the simple control of symptoms to more ambitious goals which aim to permanently extinguish the inflammation, even the subclinical one. As a consequence, the role of some of the conventional drugs which have been used in CD for several years, such as 5-aminosalicylates and conventional immunosuppressants, is becoming more limited in favor of these new drugs. This profound modification of CD therapy and the intrinsic complexity of the disease are relevant to the point that the management of inflammatory bowel diseases is gradually becoming a subspecialty in the field of gastroenterology or internal medicine.https://www.italjmed.org/index.php/ijm/article/view/1194Biologicsclinical guidelinesrandomized controlled trialssmall molecule drugs. |
| spellingShingle | Fabio Salvatore Macaluso Medical management of Crohn’s disease: state of the art and future perspectives Italian Journal of Medicine Biologics clinical guidelines randomized controlled trials small molecule drugs. |
| title | Medical management of Crohn’s disease: state of the art and future perspectives |
| title_full | Medical management of Crohn’s disease: state of the art and future perspectives |
| title_fullStr | Medical management of Crohn’s disease: state of the art and future perspectives |
| title_full_unstemmed | Medical management of Crohn’s disease: state of the art and future perspectives |
| title_short | Medical management of Crohn’s disease: state of the art and future perspectives |
| title_sort | medical management of crohn s disease state of the art and future perspectives |
| topic | Biologics clinical guidelines randomized controlled trials small molecule drugs. |
| url | https://www.italjmed.org/index.php/ijm/article/view/1194 |
| work_keys_str_mv | AT fabiosalvatoremacaluso medicalmanagementofcrohnsdiseasestateoftheartandfutureperspectives |